|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As a tumour suppressor, FOXA2 could be responsible for <i>SLC25A13</i> high expression levels in liver and its downregulation in hepatocellular carcinoma (HCC).
|
30995827 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IMPLICATIONS: The observations provide strong genetic evidence for an opposing role of FoxM1 and FoxA2 in HCC progression.
|
30814128 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, our findings illustrated a novel feedback loop including FOXA2 and its neighboring gene lncRNA-NEF, which might provide mechanistic insights into the metastatic progress of HCC.
|
29311643 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicated that the coordination function of FOXA2 and SIRT6 played a critical role in HCC progression and may serve as potential drug candidates for HCC.
|
29535552 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This increase in FOXA2 expression resulted in upregulation of lncRNA-CPS1 intronic transcript 1 (CPS1-IT1), which reduced HIF-1α activity and consequently resulted in the suppression of epithelial-mesenchymal transition (EMT) progression and HCC metastasis.
|
29137263 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma.
|
28367241 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings indicate that FOXA2 plays a critical role in HCC metastasis and may serve as a novel therapeutic target for HCC.
|
25142974 |
2014 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that HNF-3β protein levels were consistently upregulated in HCC clinical tissues compared with matched normal adjacent tissues.
|
25425543 |
2014 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Functional studies in human hepatocellular carcinoma cells showed that rs2073658 is located in a forkhead box A2 (FOXA2) binding site and that major allele constructs displayed higher transcriptional activity than minor allele constructs.
|
22460558 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.
|
14739090 |
2004 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Human hepatoma (HepG2) cotransfection assays demonstrated that HNF-6 synergistically stimulated FoxA2 but not FoxA1 or FoxA3 transcriptional activity, and protein-binding assays showed that this protein interaction required the HNF-6 Cut-Homeodomain and FoxA2 winged-helix DNA binding domains.
|
12509444 |
2003 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human hepatoma (HepG2) cotransfection assays demonstrated that HNF-6 synergistically stimulated FoxA2 but not FoxA1 or FoxA3 transcriptional activity, and protein-binding assays showed that this protein interaction required the HNF-6 Cut-Homeodomain and FoxA2 winged-helix DNA binding domains.
|
12509444 |
2003 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to define HNF-3 beta protein domains involved in transcriptional activation, we have used a reporter gene, whose transcription is dependent on HNF-3 binding, for hepatoma cell cotransfection assays with expression vectors that produced different truncated HNF-3 beta proteins.
|
1324404 |
1992 |